Deuruxolitinib: a new entry in the dm+d dictionary
The NHS Business Services Authority has added deuruxolitinib to the dm+d (Dictionary of Medicines and Devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of targeted immunosuppressive agents increasingly used in dermatology and rheumatology.
What is deuruxolitinib used for?
Deuruxolitinib is indicated for the treatment of atopic dermatitis (eczema). It works by inhibiting JAK1, a key enzyme in the inflammatory cascade that drives allergic and autoimmune skin conditions. However, it is important to note that deuruxolitinib is not currently approved for use in the UK and is not available on the NHS.
Event medicine relevance
Because deuruxolitinib is not licensed in the UK, it is not appropriate for event medicine use. Medical responders should not administer this agent at events. However, you may encounter patients who are taking deuruxolitinib if they have obtained it privately, through clinical trials, or whilst travelling abroad.
If a patient reports taking deuruxolitinib and presents with acute exacerbation of atopic dermatitis or other acute symptoms, advise them to seek specialist dermatology review and arrange conveyance to hospital if clinically indicated.
Key points for responders
- Not licensed in the UK — do not administer
- JAK inhibitors carry a risk profile that requires specialist monitoring
- If encountered, treat the acute presentation symptomatically and refer to hospital
- Always verify current licensing status against the BNF and MHRA before considering any clinical use
Further information
For the latest guidance on JAK inhibitors and atopic dermatitis management, consult the BNF and the MHRA.
This entry has been added to the NHS BSA dm+d dictionary for reference and awareness purposes.